Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review.

ABSTRACT: BACKGROUND:Immune checkpoint inhibitors (ICIs), targeting CTLA-4 or PD-1 molecules, have shown impressive therapeutic results. However, only 20-40% of advanced melanoma patients have durable responses to ICI, and these positive effects must be balanced against severe off-target immune toxicity and high costs. This urges the development of predictive biomarkers for ICI response to select patients with likely clinical benefit from treatment. Although many candidate biomarkers exist, a systematic overview of biomarkers and their usefulness is lacking. OBJECTIVES:Here, we systematically review the current literature of clinical data of ICI treatment to provide an overview of candidate predictive biomarkers for ICI in melanoma patients. METHODS:To identify studies on biomarkers for clinical res

SUBMITTER: Jessurun CAC 

PROVIDER: S-EPMC5625582 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature